CMTNS and ONLS , with a significant improvement of respectively of @ % ( @ % - @ % ) and @ % ( @ % - @ % ) in the HD group versus the pool of all other groups , appear to be the most sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo .